NEW YORK, NY / ACCESSWIRE / November 16, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Amarin Corporation Plc (NASDAQ:AMRN)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/amarin-corporation-plc-loss-submission-form?prid=21250&wire=1
Lead Plaintiff Deadline: December 23, 2021
Class Period: December 5, 2018 - June 21, 2021
Allegations against AMRN include that: (i) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (ii) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (iii) the Company's litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company's business and future prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
On24, Inc. (NYSE:ONTF)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/on24-inc-loss-submission-form?prid=21250&wire=1
Lead Plaintiff Deadline: January 3, 2022
This lawsuit is on behalf of persons and entities who also acquired ON24's shares pursuant and traceable to the Company's February 2, 2021, initial public offering.
Allegations against ONTF include that: the surge in COVID-19 customers observed in the lead up to the IPO consisted of a significant number that did not fit ON24's traditional customer profile, and, as a result, were significantly less likely to renew their contracts.
Novavax, Inc. (NASDAQ:NVAX)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/novavax-inc-loss-submission-form-2?prid=21250&wire=1
Lead Plaintiff Deadline: January 11, 2022
Class Period: March 2, 2021 - October 19, 2021
Allegations against NVAX include that: (i) Novavax overstated its manufacturing capabilities and downplayed manufacturing issues that would impact its approval timeline for NVX-CoV2373, a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 coronavirus; (ii) as a result, Novavax was unlikely to meet its anticipated Emergency Use Authorization regulatory timelines for NVX-CoV2373; (iii) accordingly, the Company overstated the regulatory and commercial prospects for NVX-CoV2373; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong